2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Biologic Drugs For Cancer
Biologic drugs have transformed cancer treatment by harnessing the body's immune system and targeting specific cellular mechanisms in cancer. Derived from living organisms, these innovative therapies include monoclonal antibodies, immune checkpoint inhibitors, and CAR T-cell treatments. Monoclonal antibodies, such as trastuzumab and rituximab, target cancer cell antigens to enhance immune responses or deliver toxic agents directly to cancer cells. Immune checkpoint inhibitors, like pembrolizumab, work by removing inhibitory signals on immune cells, allowing them to more effectively combat cancer. CAR T-cell therapies involve modifying a patient's T-cells to recognize and destroy cancer cells more efficiently. These biologic treatments provide highly personalized and precise options, often with reduced side effects, marking a significant advancement in cancer therapy.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China